Stockscreener 앱 받기
78.75
2.23%
1.73
전일 마감가:
$77.02
열려 있는:
$77.51
하루 거래량:
3.23M
Relative Volume:
0.39
시가총액:
$100.17B
수익:
$402.11B
순이익/손실:
$1.73B
주가수익비율:
57.11
EPS:
1.3789
순현금흐름:
$7.81B
1주 성능:
+3.16%
1개월 성능:
-2.02%
6개월 성능:
+20.20%
1년 성능:
+24.55%
1일 변동 폭
$77.08
$79.06
1주일 범위
$73.00
$79.06
52주 변동 폭
$58.35
$85.15
CVS헬스 Stock (CVS) Company Profile
명칭
Cvs Health Corp
전화
(401) 765-1500
주소
ONE CVS DR., WOONSOCKET
Compare CVS vs UNH, CI, ELV, HUM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CVS
Cvs Health Corp
|
78.74 | 97.99B | 402.11B | 1.73B | 7.81B | 1.3789 |
|
UNH
Unitedhealth Group Inc
|
282.11 | 252.65B | 447.57B | 12.81B | 16.08B | 13.19 |
|
CI
Cigna Group
|
291.40 | 77.65B | 216.66B | 6.25B | 7.44B | 22.19 |
|
ELV
Elevance Health Inc
|
341.10 | 72.89B | 199.13B | 5.66B | 3.17B | 25.11 |
|
HUM
Humana Inc
|
179.89 | 21.10B | 126.36B | 1.30B | 1.55B | 10.67 |
CVS헬스 Stock (CVS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-14 | 개시 | Goldman | Buy |
| 2025-08-18 | 업그레이드 | UBS | Neutral → Buy |
| 2025-08-14 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2025-02-13 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-02-12 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2025-01-30 | 업그레이드 | Edward Jones | Hold → Buy |
| 2024-12-03 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-11-18 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-10-10 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2024-10-04 | 업그레이드 | TD Cowen | Hold → Buy |
| 2024-05-30 | 개시 | Robert W. Baird | Neutral |
| 2024-05-07 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2024-05-02 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-05-01 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2024-05-01 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-03-06 | 개시 | Barclays | Equal Weight |
| 2024-02-26 | 개시 | Leerink Partners | Outperform |
| 2023-12-22 | 개시 | HSBC Securities | Buy |
| 2023-09-19 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-09-12 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2023-08-18 | 다운그레이드 | Edward Jones | Buy → Hold |
| 2023-05-26 | 개시 | Piper Sandler | Overweight |
| 2023-04-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-01-03 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-11-23 | 재개 | Morgan Stanley | Overweight |
| 2022-06-17 | 개시 | Loop Capital | Buy |
| 2022-05-27 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2022-03-29 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2022-02-11 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2021-12-14 | 개시 | Goldman | Buy |
| 2021-12-01 | 개시 | Seaport Research Partners | Buy |
| 2021-05-19 | 개시 | Wells Fargo | Equal Weight |
| 2021-03-17 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-01-08 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-09-17 | 개시 | Piper Sandler | Overweight |
| 2020-07-01 | 개시 | SVB Leerink | Mkt Perform |
| 2020-05-14 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-09-27 | 재개 | RBC Capital Mkts | Outperform |
| 2019-09-12 | 개시 | Deutsche Bank | Buy |
| 2019-06-05 | 업그레이드 | Standpoint Research | Hold → Buy |
| 2019-04-29 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2019-04-18 | 개시 | Guggenheim | Buy |
| 2019-04-15 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2019-04-10 | 재확인 | BofA/Merrill | Buy |
| 2019-03-13 | 개시 | Bernstein | Outperform |
| 2019-02-20 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2019-01-17 | 개시 | UBS | Buy |
| 2018-12-18 | 개시 | Barclays | Overweight |
| 2018-11-29 | 재개 | Goldman | Neutral |
| 2018-11-28 | 개시 | Evercore ISI | Outperform |
| 2018-10-26 | 재개 | Wolfe Research | Peer Perform |
| 2018-07-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2018-02-27 | 재개 | BofA/Merrill | Buy |
| 2018-02-13 | 재확인 | Citigroup | Neutral |
모두보기
CVS헬스 주식(CVS)의 최신 뉴스
Analysts See Multiple Growth Levers For CVS In 2026 - Benzinga
Analysts See Multiple Growth Levers For CVS Health In 2026 - Benzinga
Is CVS’s Reaffirmed 2026 EPS Guidance Amid Medicare Advantage Uncertainty Altering The Investment Case For CVS Health (CVS)? - Yahoo Finance
Humana’s profit outlook adds to health insurance gloom - Modern Healthcare News
CVS Q4 Deep Dive: Pharmacy Turnaround and Regulatory Shifts Shape Outlook - Finviz
Mark Cuban Urges Trump To 'Put His Weight Behind' Josh Hawley, Elizabeth Warren's 'Break Up Big Medicine Act' - Benzinga
Decoding CVS Health Corp (CVS): A Strategic SWOT Insight - GuruFocus
CVS defends its scale as CEO Joyner aligns with Trump, blames pharma for high costs - The Business Journals
CVS Health Earnings Call: Cash, Growth And Cost Risks - TipRanks
CVS annual profit guidance misses Wall Street estimates - The Boston Globe
CVS Health Corp (CVS) Q4 2025 Earnings Call Highlights: Strong R - GuruFocus
CVS Reiterates 2026 Profit Outlook, Shares Slide 3.7% Despite Q4 Beat - TradingView
CVS year-end profit falls to $1.7B in 2025 - Providence Business News
What's Going On With CVS Health Stock Tuesday?CVS Health (NYSE:CVS) - Benzinga
House subpoenas CVS, Kaiser Permanente, others in ACA fraud probe - Modern Healthcare News
Gold Moves Lower; CVS Health Earnings Top Views - Benzinga
CVS Health (CVS) Q4 2025 revenue rises 8%; adjusted earnings decline - AlphaStreet News
CVS Health (CVS) Surpasses Expectations with Strong 2025 Performance - GuruFocus
CVS Health grapples with high costs, strategic reset - Modern Healthcare News
CVS Health Reports Strong Q4 2025 Earnings with Positive Outlook - Intellectia AI
CVS Earnings: 2026 Guidance Maintained After Strong Trends In Late 2025 - Morningstar
CVS Anticipates Medicare Margin Growth by 2026 - GuruFocus
CVS Faces Challenges with Proposed Rates Amid Rising Costs - GuruFocus
Jim Cramer on CVS: "I Think It's a Fascinating Time to Own the Stock" - Finviz
Jim Cramer on CVS: “I Think It’s a Fascinating Time to Own the Stock” - Insider Monkey
CVS Health Q4 2025 slides: Revenue jumps 8.2%, stock falls despite earnings beat - Investing.com
CVS Health posts strong Q4 revenue, raises full-year guidance - Proactive financial news
Earnings call transcript: CVS Health Q4 2025 beats forecasts, stock dips By Investing.com - Investing.com India
CVS Keeps 2026 Forecast Steady Amid Tumult in Health Insurance - Bloomberg
Earnings call transcript: CVS Health Q4 2025 beats forecasts, stock dips - Investing.com
CVS Health (CVS) Subpoenaed in ACA Fraud Investigation - GuruFocus
AI for investors - MLQ.ai
CVS Beats Q4 Revenue Estimates, Highlights Strategic Growth - GuruFocus
CVS Forecasts FY26 Operating Income in Billions - GuruFocus
CVS Maintains FY26 Effective Tax Rate Projection at 25.3% - GuruFocus
Republican-led House panel issues subpoenas to eight health insurers: Axios - CNBC
CVS Health Reports Q4 Beat but Maintains Full-Year Outlook - Intellectia AI
CVS Health (NYSE:CVS) Surprises With Q4 CY2025 Sales - Finviz
CVS Health Corp (NYSE:CVS) Beats Q4 Estimates but Shares Dip on Cautious Outlook - ChartMill
CVS Lowers Fiscal Year 2026 Cash Flow Outlook - GuruFocus
CVS Health (CVS) Surpasses Q4 Expectations with Strong Revenue G - GuruFocus
CVS Health beats Q4 expectations, cash flow guidance lowered - Investing.com
CVS Health Insiders Placed Bullish Bets Worth US$2.10m - Yahoo Finance
CVS HEALTH Corp SEC 10-K Report - TradingView
CVS Health Corp earnings beat by $0.09, revenue topped estimates - Investing.com
CVS Health keeps in place 2026 forecast, eyes topping it - Reuters
CVS Health beats quarterly profit expectations on pharmacy performance - Yahoo Finance
CVS posts Q4 sales of $105.7B, up 8.2% - breakingthenews.net
US House panel issues subpoenas to eight health insurers on alleged Obamacare fraud - Reuters
Coca-Cola, CVS Health And 3 Stocks To Watch Heading Into TuesdayCoca-Cola (NYSE:KO) - Benzinga
Here's what to expect at CVS's upcoming earnings call - The Business Journals
CVS헬스 (CVS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.35%
3.27%
자본화:
|
볼륨(24시간):